Home > Resources > Whitepapers > Synthetic Biology Biotechnology & AgTech

Cell and Gene Therapy

Synthetic Biology Biotechnology & AgTech

June 8, 2022

For nearly two decades, the Future Today Institute has meticulously researched macro forces of change and the emerging trends that result. Our focus: understanding how these forces and trends will shape our futures.

Spotlight

The Content Advisory

Content is everything the business creates in order to communicate. In today’s world, the way we communicate is the only thing that separates us from the next: The next click, the next competitor, the next answer. TCA – The Content Advisory is a consulting and training company; blending the art and science of intelligent content to help today’s modern business communication’s strategy.

OTHER WHITEPAPERS

Innovative strategies to maintain product integrity in Biologic andBiosimilar clinical studies

whitePaper | August 7, 2022

The number of biologic new molecular entities approved by the FDA has increased over the last five years indicates a growing focus on biosimilar.

Bioanalytical Techniques to Advance Biosimilars Development

whitePaper | August 22, 2022

Biosimilar therapies offer more unique approaches to treating patients with serious diseases, such as cancer.

Bispecific Antibodies - CMC Considerations

whitePaper | December 16, 2022

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Multi-Specific Monoclonal Antibodies

whitePaper | February 22, 2023

The reason for the rapid expansion and development of the therapeutic antibody sector is the capacity of monoclonal antibodies to precisely bind a target antigen and neutralise or promote its activity. The efficacy and safety.

Osmolality monitoring for UF/DF and CEXcapture of mAbs from mammalian cell cultures

whitePaper | July 25, 2022

The goal of each process step is to facilitate the production of a consistent product with high yield, quality, purity, and functionality. Throughout each step various Process Analytical Tools (PAT) are used to ensure quality and production metrics are maintained.

Innovative strategies to maintain product integrity in Biologic andBiosimilar clinical studies

whitePaper | August 7, 2022

The number of biologic new molecular entities approved by the FDA has increased over the last five years indicates a growing focus on biosimilar.

Bioanalytical Techniques to Advance Biosimilars Development

whitePaper | August 22, 2022

Biosimilar therapies offer more unique approaches to treating patients with serious diseases, such as cancer.

Bispecific Antibodies - CMC Considerations

whitePaper | December 16, 2022

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Multi-Specific Monoclonal Antibodies

whitePaper | February 22, 2023

Osmolality monitoring for UF/DF and CEXcapture of mAbs from mammalian cell cultures

whitePaper | July 25, 2022

The goal of each process step is to facilitate the production of a consistent product with high yield, quality, purity, and
functionality. Throughout each step various Process Analytical Tools (PAT) are used to ensure quality and production metrics
are maintained.

More Whitepapers

Cell and Gene Therapy

Synthetic Biology Biotechnology & AgTech

Spotlight

The Content Advisory

OTHER WHITEPAPERS

Innovative strategies to maintain product integrity in Biologic andBiosimilar clinical studies

Bioanalytical Techniques to Advance Biosimilars Development

Bispecific Antibodies - CMC Considerations

GMP Grade PMSF and Protease Inhibitors

Multi-Specific Monoclonal Antibodies

Osmolality monitoring for UF/DF and CEXcapture of mAbs from mammalian cell cultures

Innovative strategies to maintain product integrity in Biologic andBiosimilar clinical studies

Bioanalytical Techniques to Advance Biosimilars Development

Bispecific Antibodies - CMC Considerations

GMP Grade PMSF and Protease Inhibitors

Multi-Specific Monoclonal Antibodies

Osmolality monitoring for UF/DF and CEXcapture of mAbs from mammalian cell cultures

Spotlight

The Content Advisory

Events